Navigation Links
GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America
Date:3/9/2011

CHICAGO, March 9, 2011 /PRNewswire/ -- GlobalCare Clinical Trials, Ltd, (GlobalCare) today announced its expansion into Latin America. GlobalCare provides selected clinical study visits at convenient locations – such as in the home or alternate settings – for study patients to support phase I-IV trials in a variety of therapeutic areas, genomics and personalized medicine in all age groups. GlobalCare's patient-centric service model provides faster patient recruitment, better protocol compliance and higher retention rates, while helping to decrease the cycle of time to biopharmaceutical development and speed delivery of life-enhancing products to market for the benefit of patients worldwide.

Regulatory-compliant services provided by GlobalCare include: global project management; study drug administration; blood and other biologic sample collection; clinical assessments; patient training and education; device management; source documentation; and data collection. In addition, the company offers central and local out-patient pharmacy services including storage and distribution, compounding and dispensing, cold chain logistics, and sourcing of commercial products and devices.

Serving the Globe

GlobalCare provides services in over 20 countries and maintains a centrally managed network of multilingual country coordinators who are trained and certified on Good Clinical Practice/International Conference on Harmonization (GCP/ICH) guidelines and have in-depth knowledge of local medical practices and country cultural attitudes. The network is augmented by an extensive pool of over 20,000 qualified local traveling physicians and nurses in the United States, Canada, Australia, Europe, Israel, and now Latin America. GlobalCare's model enables patients to participate in clinical trials regardless of study duration; frequency of visits; disease state; distance to site; and/or family, work or community commitments by conducting study vis
'/>"/>

SOURCE GlobalCare Clinical Trials, Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Research and Markets ... DNA Diagnostics Market (Product types, Application, Technology, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. This new ... end users and Geography) Global Size, Industry Analysis, ...
(Date:10/22/2014)... Involution Studios , a healthcare software ... infographic, Understanding Ebola . The goal of ... to follow informative tool for anyone wanting to know ... prevention. , "As the news has spread in all ... represents not only a healthcare crisis with global impact, ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... revenue growth ... Q3 2008 Highlights: - Product revenues ... - Direct (Non-OEM) Business revenues increased by 48% ... Calif., Oct. 27 Masimo Corporation,(Nasdaq: MASI ), the inventor of Pulse ...
... as Lead Epidemiologist, RALEIGH, N.C., Oct. 27 ... today the appointment of Dr.,Jerome Wilson as Senior ... Epidemiologist, Dr. Wilson is responsible for providing consulting,services ... PRA provides extensive Phase IV Post-Marketing services to,pharmaceutical ...
... JOSE, Calif., Oct. 27 HPSI (OTC Bulletin,Board: EROX) releases ... light of events that have shaken the investment community around ... to take this opportunity to update you as to ... Excluding technology advancements, an update of which will be ...
Cached Biology Technology:Masimo Reports Third Quarter 2008 Financial Results 2Masimo Reports Third Quarter 2008 Financial Results 3Masimo Reports Third Quarter 2008 Financial Results 4Masimo Reports Third Quarter 2008 Financial Results 5Masimo Reports Third Quarter 2008 Financial Results 6Masimo Reports Third Quarter 2008 Financial Results 7Masimo Reports Third Quarter 2008 Financial Results 8Masimo Reports Third Quarter 2008 Financial Results 9Masimo Reports Third Quarter 2008 Financial Results 10Masimo Reports Third Quarter 2008 Financial Results 11Masimo Reports Third Quarter 2008 Financial Results 12Masimo Reports Third Quarter 2008 Financial Results 13Jerome Wilson Joins PRA International's Late Phase Service Group 2Human Pheromone Sciences, Inc. - Shareholder Update 2Human Pheromone Sciences, Inc. - Shareholder Update 3
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... chemical processes in cells is dictated by the speed of ... a versatile method developed at the Institute of Physical Chemistry ... able to predict for the first time the diffusion coefficients ... is important not only for biologists and chemists, but also ...
... the first medication approved for the treatment of alcoholism ... part, by preventing the metabolism of an alcohol by-product, ... cause unpleasant symptoms, including nausea, vomiting, headache, and accelerated ... to avoid drinking. Beginning in the late ...
... alone were responsible for the demise of Australia,s iconic ... new study led by the University of Adelaide has ... study contradicts the widespread belief that disease must have ... thylacine was a unique marsupial carnivore found throughout most ...
Cached Biology News:Biologistics: How fast do chemical trains move in living cells? 2Biologistics: How fast do chemical trains move in living cells? 3Disulfiram: New support for an old addiction drug 2Disease not a factor in Tassie Tiger extinction 2
... Microarray Dot Blot Kits overcome this limitation ... over a wide range in low-density protein ... They are ideal for performing reverse-phase ... samples for the presence of low abundant ...
... easy-to-use kits for arraying proteins of ... common lab equipment. DiscoverLight Protein Array ... your protein, cell lysate or antibody ... kits include specially designed nitrocellulose membranes ...
Request Info...
... StabilZyme AP Conjugate Stabilizer is an ... bovine protein and other non-toxic stabilizing ... acid), pH 5.5 6.5. ... 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ...
Biology Products: